(Q42658255)

4 November 2017

A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder (English)

1 reference

4 November 2017

Elizabeth A Hoge

4

0 references

Andrea L. Gold

object named as

Andrea L Gold

8

0 references

Rebecca K. Sripada

object named as

Rebecca E Kaufman

7

0 references

author name string

Karleyton C Evans

1

1 reference

4 November 2017

Naomi M Simon

2

1 reference

4 November 2017

Darin D Dougherty

3

1 reference

4 November 2017

John J Worthington

5

1 reference

4 November 2017

Candice Chow

6

1 reference

4 November 2017

Alan J Fischman

9

1 reference

4 November 2017

Mark H Pollack

10

1 reference

4 November 2017

Scott L Rauch

11

1 reference

4 November 2017

language of work or name

English

0 references

publication date

4 June 2008

1 reference

4 November 2017

Neuropsychopharmacology

1 reference

4 November 2017

34

1 reference

4 November 2017

390-398

1 reference

4 November 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2008.69

4 November 2017

0 references

cites work

Cognitive neuroscience of human social behaviour

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Neurobiological mechanisms of the placebo effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Response and habituation of the human amygdala during visual processing of facial expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Tiagabine for the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Tiagabine for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Using neuroimaging to predict treatment response in mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Emotional valence modulates activity in the posterior fusiform gyrus and inferior medial prefrontal cortex in social perception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Pharmacotherapy for social anxiety disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Molecular targets in the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

The neural correlates of social anxiety disorder and response to pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Reduced serotonin-1A receptor binding in social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

The functional neuroanatomy of the placebo effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Dissociable medial prefrontal contributions to judgments of similar and dissimilar others.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Architectonic subdivision of the human orbital and medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Extinction learning in humans: role of the amygdala and vmPFC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Prefrontal mechanisms in extinction of conditioned fear.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA(A) receptor function in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Dissociable prefrontal networks for cognitive and affective theory of mind: a lesion study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Increased amygdala activation to angry and contemptuous faces in generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Common and distinct brain activation to threat and safety signals in social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Why do some individuals develop social phobia? A review with emphasis on the neurobiological influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

A PET provocation study of generalized social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

The role of the medial prefrontal cortex-amygdala circuit in stress effects on the extinction of fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

7 January 2021

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

7 January 2021

An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

7 January 2021

Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.69

7 January 2021

Identifiers

DOI

10.1038/NPP.2008.69

1 reference

Dimensions Publication ID

4 November 2017

0 references

1 reference